logo
  

Novartis Invests $250 Mln To Advance R&D Of Treatments Against Neglected Tropical Diseases & Malaria

Novartis (NVS) said it will invest $250 million to advance research and development of new treatments to combat neglected tropical diseases and malaria, as part of its commitment over five years (2021-2025).

The commitment includes $100 million to advance R&D for Chagas disease, leishmaniasis, dengue and cryptosporidiosis, and $150 million for next-generation antimalarials and a new formulation for babies under 5kg with malaria.

"Today, by endorsing the Kigali Declaration and pledging to invest USD 250 million, we aim to accelerate progress toward elimination of these diseases, which continue to cause suffering and stigma for millions of people around the globe," said Vas Narasimhan, CEO of Novartis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT